STOCK TITAN

Marker Therapeutics Inc - MRKR STOCK NEWS

Welcome to our dedicated news page for Marker Therapeutics (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Marker Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Marker Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.82%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
conferences
Marker Therapeutics Inc

Nasdaq:MRKR

MRKR Rankings

MRKR Stock Data

38.53M
6.74M
12.19%
22.99%
1.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Jacksonville

About MRKR

tapimmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. the company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). the company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer t-cells and helper t-cells to destroy cancer cells, and they are designed to work with 80% of the population. tapimmune is advancing two clinical stage t-cell vaccine candidates in multiple phase ii and phase ib/iia clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from fda fast track and orphan disease designation. the company is working in collaboration with industry and clini